NIKKEI 225
38,228.76 -606.34 (-1.56%) HANG SENG
18,422.58 -56.79 (-0.31%) CRUDE OIL
77.95 -0.43 (-0.55%) GOLD FUTURES
2,326.90 +2.70 (+0.12%) DOW
38,884.26 +31.99 (+0.08%) Bitcoin GBP
50,205.92 -498.14 (-0.98%)
Poxel S.A. (7PO.F)
| Previous close | 0.6390 |
| Open | 0.6390 |
| Bid | 0.6450 x 131600 |
| Ask | 0.6560 x 130400 |
| Day's range | 0.5860 - 0.6450 |
| 52-week range | 0.1990 - 0.8270 |
| Volume | |
| Avg. volume | 84 |
| Market cap | 25.092M |
| Beta (5Y monthly) | 1.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.0800 |
| Earnings date | 16 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WirePoxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release
LYON, France, April 29, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today reported its cash position, provided a financial and business update for the first quarter ended March 31, 2024, and announced the postponement of its 2023 full-year results re
Business WirePoxel to Report Its 2023 Annual Results by the End of April 2024
LYON, France, March 28, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announces the publication at the end of April 2024 of its 2023 Annual Results, originally scheduled for April 9, 2024, given the expected completion of a transaction by the end of April.
Business WirePoxel Reports Cash and Revenue for the Full Year 2023 and Provides Corporate Update
LYON, France, February 15, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its cash position and revenue and provided a corporate update for the twelve months ended December 31, 2023.
